Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingCellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.
Vonetize Plc: Update regarding the sale of the controlling shareholders’ shares to US based Desilu Studios Inc.; target price unchanged at NIS 1.43 Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingVonetize Plc: Update regarding the sale of the controlling shareholders’ shares to US based Desilu Studios Inc.; target price unchanged at NIS 1.43
Vonetize Plc: Growth in Revenues from a quarterly perspective; operational delay in Russia; forecasted revenues have decreased from previous estimate; target price reduced to NIS 1.43 Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingVonetize Plc: Growth in Revenues from a quarterly perspective; operational delay in Russia; forecasted revenues have decreased from previous estimate; target price reduced to NIS 1.43
Vonetize Plc: Agreements signed with content providers expand operations to the US, LATAM, Africa, CIS and Europe; purchase of controlling interest by Desilu Studios Inc. materially confirms market potential for its product; target price raised to NIS 1.85 Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingVonetize Plc: Agreements signed with content providers expand operations to the US, LATAM, Africa, CIS and Europe; purchase of controlling interest by Desilu Studios Inc. materially confirms market potential for its product; target price raised to NIS 1.85
Brainsway Ltd: The company’s main competitor has completed an IPO, providing for a new benchmark to Brainsway’s valuation; target price unchanged. Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingBrainsway Ltd: The company’s main competitor has completed an IPO, providing for a new benchmark to Brainsway’s valuation; target price unchanged.
RedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018. Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingRedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018.
RedHill Biopharma: Net revenues for 2017 totaled $4M, and met our expectations. We expect Redhill to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; Price target raised to NIS 2.59 Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingRedHill Biopharma: Net revenues for 2017 totaled $4M, and met our expectations. We expect Redhill to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; Price target raised to NIS 2.59
Safe-T: A Promising Entry Point to the Global Cybersecurity Technologies Industry Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingSafe-T: A Promising Entry Point to the Global Cybersecurity Technologies Industry
Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38 Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingSafe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38
RedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27. Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingRedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27.
